

VIVIMED LABS LIMITED

CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED DECEMBER 31, 2013

in Lakhs

Sl. No.	Particulars	Quarter Ended				9 Months Ended		Previous Year ended (FY13)
		31.12.2013	30.09.2013	31.12.2012	31.12.2013	31.12.2012	(Audited)	
<b>1</b>	<b>Income From Operations</b>	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
	(a) Net Sales / Income from Operations (Net of Excise Duty)	33,526.56	30,663.98	27,211.94	98,265.98	81,072.52	1,10,879.56	
	(b) Other Operating Income	50.77	64.29	226.85	431.09	1,361.41	1,187.55	
	<b>Total Income From Operations (Net)</b>	<b>33,577.33</b>	<b>30,728.27</b>	<b>27,438.79</b>	<b>98,697.07</b>	<b>82,433.93</b>	<b>1,12,066.91</b>	
	a. Cost of Raw Materials Consumed	17,476.65	14,611.85	13,990.81	47,127.55	40,457.96	53,743.28	
	b. Purchase of Stock in Trade	-	-	-	-	-	-	
	c. Changes in Inventories of finished Inventories of Finished Goods, Work-in-Progress and Stock in Trade	(1,489.44)	1,228.40	(45.46)	2,456.53	(2,496.96)	(2,415.90)	
	d. Employee Benefit Expenses	1,904.37	1,645.59	932.73	5,106.05	3,597.40	5,032.73	
	e. Depreciation and Amortisation Expenses	1,693.98	1,737.25	1,429.18	4,896.66	4,248.97	5,881.08	
	f. Other Expenditure	10,325.64	8,003.59	8,845.77	28,524.54	25,597.64	35,944.97	
	<b>Total Expenses</b>	<b>29,911.20</b>	<b>27,226.67</b>	<b>25,153.03</b>	<b>89,111.33</b>	<b>71,405.02</b>	<b>98,186.17</b>	
<b>2</b>	<b>Profit / (loss) from Operations before Other Income, Finance Costs and exceptional items (1 - 2)</b>	<b>3,666.13</b>	<b>3,501.60</b>	<b>2,285.76</b>	<b>10,585.74</b>	<b>11,028.91</b>	<b>13,880.74</b>	
<b>3</b>	<b>Profit / (loss) from Ordinary Activities before Finance Costs and exceptional items (3 - 4)</b>	<b>3,666.13</b>	<b>3,501.60</b>	<b>2,285.76</b>	<b>10,585.74</b>	<b>11,028.91</b>	<b>13,880.74</b>	
<b>4</b>	<b>Other Income</b>	-	-	-	-	-	-	
<b>5</b>	<b>Profit / (loss) from Ordinary Activities before Finance Costs and exceptional items (3 - 4)</b>	<b>3,666.13</b>	<b>3,501.60</b>	<b>2,285.76</b>	<b>10,585.74</b>	<b>11,028.91</b>	<b>13,880.74</b>	
<b>6</b>	<b>Finance Costs</b>	1,564.84	1,715.11	984.19	4,265.60	3,648.65	4,093.18	
<b>7</b>	<b>Profit / (loss) from Ordinary Activities after Finance Costs but before exceptional items (5 - 6)</b>	<b>2,101.29</b>	<b>1,786.49</b>	<b>1,301.57</b>	<b>6,320.14</b>	<b>7,400.26</b>	<b>9,787.56</b>	
<b>8</b>	<b>Exceptional items</b>	-	-	-	-	-	-	
<b>9</b>	<b>Profit / Loss from ordinary activities before Tax (7 - 8)</b>	<b>2,101.29</b>	<b>1,786.49</b>	<b>1,301.57</b>	<b>6,320.14</b>	<b>7,400.26</b>	<b>9,787.56</b>	
<b>10</b>	<b>Tax Expenses</b>	202.48	148.51	(391.28)	784.91	540.76	1,429.15	
<b>11</b>	<b>Net Profit / Loss from ordinary activities after Tax (9 - 10)</b>	<b>1,898.81</b>	<b>1,637.98</b>	<b>1,692.85</b>	<b>5,535.23</b>	<b>6,859.51</b>	<b>8,358.41</b>	
<b>12</b>	<b>Extraordinary Items (net of tax expenses Rs...../Lacs)</b>	-	-	-	-	-	-	
<b>13</b>	<b>Net Profit / Loss for period (11 - 12)</b>	<b>1,898.81</b>	<b>1,637.98</b>	<b>1,692.85</b>	<b>5,535.23</b>	<b>6,859.51</b>	<b>8,358.41</b>	
<b>14</b>	<b>Share of Profit / (Loss) of associates</b>	-	-	-	-	-	-	
<b>15</b>	<b>Minority Interest</b>	-	-	-	-	-	-	
<b>16</b>	<b>Net Profit / Loss after taxes, Minority Interest and Share of Profit / (Loss) of Associates (13 - 14 - 15)</b>	<b>1,898.81</b>	<b>1,637.98</b>	<b>1,692.85</b>	<b>5,535.23</b>	<b>6,859.51</b>	<b>8,358.41</b>	
<b>17</b>	<b>Paid up Equity Share Capital (Face value of the Share shall be indicated)</b>	1,620.38	1,620.38	1,393.39	1,620.38	1,393.39	1,606.09	
<b>18</b>	<b>Reserve excluding Revaluation Reserves as per Balance Sheet of Previous Accounting Year</b>	-	-	-	-	-	-	
<b>19</b>	<b>Earnings per Share (before Extraordinary Items) [of Rs. 10/- each] (not annualised)</b>	11.72	10.11	12.15	34.16	49.23	52.04	
	(a) Basic	11.72	10.11	12.15	34.16	49.23	52.04	
	(b) Diluted	11.72	10.11	10.54	34.16	42.71	52.04	

1. The above Consolidated Unaudited Financial Results for the Quarter ended December 31, 2013 have been reviewed by Audit Committee and taken on record by Board of Directors at their meeting held on 13<sup>th</sup> February, 2014.

2. Consolidated Financial Statements have been prepared in accordance with Accounting Standard 21 issued by ICAI. Consolidated Results are combined numbers of Vivimed Labs Limited and its direct wholly owned subsidiaries, viz. (i) Creative Healthcare Private Limited, (ii) Vivimed Labs USA, Inc., (iii) Kior Sahen Private Limited, (iv) Octantis Nobel Labs Private Limited, (v) Vivimed Labs (Alabur) Pvt (td)(vi) Finoo Pharma Pvt Ltd (vii) Vivimed Holdings Limited and its step down subsidiary Vivimed Labs Europe Limited (viii) Vivimed Labs Mountbus Limited and its step down subsidiaries (ix) Vivimed Labs UK Limited, (x) Vivimed Labs Spain, S.L. (xi) Union Quimico Farmaceutico S.A.U., Spain, (xii) Holiday International Limited, UK. & (xiii) Uquifo Mexico S. A. de C.V.

3. The Company opted to publish only Consolidated Financial Results. Standalone results of the Company will be available on Company's website www.vivimedlabs.com and also on BSE & NSE websites.

4. As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two Segments "Specialty Chemicals" and "Pharma" are reported.

5. Corresponding numbers of previous period / year have been revised, regrouped, wherever necessary.

For VIVIMED LABS LIMITED

(SAVITOSH VABALWARI)

MANAGING DIRECTOR & CEO

Place : Hyderabad  
Date : 13.02.2014

**VIVIMED LABS LIMITED**  
**SEGMENT-WISE CONSOLIDATED FINANCIAL RESULTS AND CAPITAL EMPLOYED UNDER CLAUSE - 41 OF THE LISTING AGREEMENT**

in Lakhs

Particulars	3 Months Ended			9 Months Ended		Year Ended 31.03.2013 (Audited)
	31.12.2013 (Unaudited)	30.09.2013 (Unaudited)	31.12.2012 (Unaudited)	31.12.2013 (Unaudited)	31.12.2012 (Unaudited)	
<b>1. Segment Revenue</b> (net sales/income from each segment should be disclosed under this head)						
a. Speciality Chemicals Business	10,741.09	9,937.67	9,552.25	30,512.52	35,292.35	37,038.67
b. Pharma Business	22,785.47	20,726.31	17,659.69	67,753.46	45,780.17	73,840.89
<b>Total</b>	<b>33,526.56</b>	<b>30,663.98</b>	<b>27,211.94</b>	<b>98,265.98</b>	<b>81,072.52</b>	<b>1,10,879.56</b>
Less, Inter Segment Revenue						
<b>Net sales / Income from Operations</b>	<b>33,526.56</b>	<b>30,663.98</b>	<b>27,211.94</b>	<b>98,265.98</b>	<b>81,072.52</b>	<b>1,10,879.56</b>
<b>2. Segment Results (Profit) (+) / Loss (-) before tax and interest from each segment</b>						
a. Speciality Chemicals Business	2,204.71	2,113.11	1,425.20	5,817.05	5,291.45	6,826.37
b. Pharma Business	1,461.41	1,388.49	860.55	4,768.70	5,757.45	7,054.37
<b>Total</b>	<b>3,666.13</b>	<b>3,501.60</b>	<b>2,285.75</b>	<b>10,585.75</b>	<b>11,048.91</b>	<b>13,880.74</b>
Less: 1. Interest	1,564.84	1,715.11	984.19	4,265.60	3,648.65	4,093.18
2. Other Un-allocable Expenditure						
3. Un-allocable Income						
<b>Total Profit Before Tax</b>	<b>2,101.28</b>	<b>1,786.49</b>	<b>1,301.56</b>	<b>6,320.15</b>	<b>7,400.26</b>	<b>9,787.56</b>
<b>3. Capital Employed</b>						
a. Speciality Chemicals Business	82,619.78	80,666.88	78,450.64	82,619.78	78,450.64	77,724.60
b. Pharma Business	63,246.47	60,838.64	47,961.24	63,246.47	47,961.24	51,568.93
<b>Total</b>	<b>1,45,866.25</b>	<b>1,41,505.52</b>	<b>1,26,411.87</b>	<b>1,45,866.25</b>	<b>1,26,411.87</b>	<b>1,29,293.52</b>

For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)

MANAGING DIRECTOR & CEO

Place : Hyderabad

Date :13.02.2014

**STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED DECEMBER 31ST, 2013**

VIMMED LABS LIMITED

Sl. No.	Particulars	Quarter Ended					9 Months Ended	(INR in Lacs)
		31.12.2013 (Unaudited)	30.09.2013 (Unaudited)	31.12.2012 (Unaudited)	31.12.2013 (Unaudited)	31.12.2012 (Unaudited)		
1	Income from Operations							
	(a) Net Sales / Income from Operations (Net of Excise Duty)	10,339.97	10,227.74	11,413.05	30,418.34	31,487.53	42,312.51	
	(b) Other Operating Income	58.09	10.03	68.44	82.97	262.93	337.93	
	<b>Total Income From Operations (Net)</b>	<b>10,398.05</b>	<b>10,237.77</b>	<b>11,481.48</b>	<b>30,501.31</b>	<b>31,750.46</b>	<b>42,650.44</b>	
	a. Cost of Raw Materials Consumed	5,665.09	5,703.56	6,464.67	16,774.99	18,987.61	24,736.98	
	b. Purchase of Stock in Trade							
	c. Changes in Inventories of finished Inventories of finished Goods, Work-in-Progress and Stock in Trade	(67.30)	39.71	484.36	375.79	(899.80)	(755.32)	
	d. Employee Benefit Expenses	636.21	620.66	311.96	1,767.82	1,067.93	1,550.85	
	e. Depreciation and Amortisation Expenses	456.00	489.47	385.00	1,351.64	1,137.73	1,770.68	
	f. Other Expenditure	1,748.11	1,254.90	1,779.31	4,520.18	5,313.78	7,415.35	
2	<b>Total Expenses</b>	<b>8,436.71</b>	<b>8,108.31</b>	<b>9,425.30</b>	<b>24,790.43</b>	<b>25,607.24</b>	<b>34,668.54</b>	
3	<b>Profit / (Loss) from Operations before Other Income, Finance Costs and exceptional items (1 - 2)</b>	<b>1,959.34</b>	<b>2,129.46</b>	<b>2,056.18</b>	<b>5,710.88</b>	<b>6,143.22</b>	<b>7,981.90</b>	
4	Other Income							
5	<b>Profit / (Loss) from Ordinary Activities before Finance Costs and exceptional items (3 - 4)</b>	<b>1,959.34</b>	<b>2,129.46</b>	<b>2,056.18</b>	<b>5,710.88</b>	<b>6,143.22</b>	<b>7,981.90</b>	
6	Finance Costs	1,093.64	1,264.57	787.10	2,941.74	2,362.92	2,843.78	
7	<b>Profit / (Loss) from Ordinary Activities after Finance Costs but before exceptional items (5 - 6)</b>	<b>865.70</b>	<b>864.89</b>	<b>1,269.08</b>	<b>2,769.14</b>	<b>3,780.30</b>	<b>5,138.12</b>	
8	Exceptional Items							
9	<b>Profit / Loss from ordinary activities before Tax (7 - 8)</b>	<b>865.70</b>	<b>864.89</b>	<b>1,269.08</b>	<b>2,769.14</b>	<b>3,780.30</b>	<b>5,138.12</b>	
10	Tax Expenses	173.14	172.98	243.71	553.83	992.84	1,464.55	
11	<b>Net Profit / Loss from ordinary activities after Tax (9 - 10)</b>	<b>692.56</b>	<b>691.91</b>	<b>1,025.37</b>	<b>2,215.31</b>	<b>2,787.46</b>	<b>3,673.57</b>	
12	Extraordinary Items (net of tax expenses Rs.....(Lacs))							
13	<b>Net Profit / Loss for period (11 - 12)</b>	<b>692.56</b>	<b>691.91</b>	<b>1,025.37</b>	<b>2,215.31</b>	<b>2,787.46</b>	<b>3,673.57</b>	
14	Share of Profit / (Loss) of associates							
15	Minority Interest							
16	<b>Net Profit / Loss after taxes, Minority Interest and share of Profit / (Loss) of Associates (13 - 14 - 15)</b>	<b>692.56</b>	<b>691.91</b>	<b>1,025.37</b>	<b>2,215.31</b>	<b>2,787.46</b>	<b>3,673.57</b>	
17	Paid up Equity Share Capital (Face value of the Share shall be indicated)	1,620.38	1,620.38	1,393.39	1,620.38	1,393.39	1,606.09	
18	Reserve excluding Revaluation Reserve as per Balance Sheet of Previous Accounting Year							
19	Earnings per Share (before Extraordinary Items) (of Rs.10/- each) (not annualised)	4.27	4.27	7.36	13.67	20.00	22.87	
	(a) Basic							
	(b) Diluted	4.27	4.27	6.38	13.67	17.36	22.87	

1. The above Standalone Unaudited Financial Results for the Quarter ended 31ST DECEMBER, 2013 have been reviewed by Audit Committee and token on record by Board of Directors at their meeting held on 13TH FEBRUARY 2014.

2. The Company opted to publish only Consolidated Financial Results. Standalone results of the Company will be available on Company's website www.vimmedlabs.com and also on BSE & NSE websites.

3. As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two Segments "Specialty Chemicals" and "Pharma" are reported.

4. Corresponding numbers of previous period / year have been revised, regrouped, wherever necessary.

For VIMMED LABS LIMITED  
(SANTOSH VARALIMAR)  
MANAGING DIRECTOR & CEO

Place : Hyderabad  
Date : 13.02.2014

**VIVIMED LABS LIMITED**  
**SEGMENT-WISE STANDALONE FINANCIAL RESULTS AND CAPITAL EMPLOYED UNDER CLAUSE - 41 OF THE LISTING AGREEMENT**

in Lakhs

Particulars	3 Months Ended			9 Months Ended			Year Ended 31.03.2013 (Audited)
	31.12.2013 (Unaudited)	30.09.2013 (Unaudited)	31.12.2012 (Unaudited)	31.12.2013 (Unaudited)	31.12.2012 (Unaudited)	31.03.2013 (Audited)	
<b>1. Segment Revenue</b> (net sales/income from each segment should be disclosed under this head)							
a. Speciality Chemicals Business	8,511.31	8,585.39	8,853.10	24,671.80	24,283.87	32,864.44	
b. Pharma Business	1,828.66	1,642.35	2,559.94	5,746.54	7,203.66	9,448.07	
<b>Total</b>	<b>10,339.97</b>	<b>10,227.74</b>	<b>11,413.04</b>	<b>30,418.34</b>	<b>31,487.53</b>	<b>42,312.51</b>	
Less, Inter Segment Revenue							
<b>Net sales / Income from Operations</b>	<b>10,339.97</b>	<b>10,227.74</b>	<b>11,413.04</b>	<b>30,418.34</b>	<b>31,487.53</b>	<b>42,312.51</b>	
<b>2. Segment Results (Profit) (+) / Loss (-) before tax and interest from each segment</b>							
a. Speciality Chemicals Business	1,724.02	1,921.46	1,481.47	4,823.38	4,805.43	6,410.83	
b. Pharma Business	235.32	208.01	574.70	887.50	1,337.78	1,571.07	
<b>Total</b>	<b>1,959.35</b>	<b>2,129.47</b>	<b>2,056.17</b>	<b>5,710.88</b>	<b>6,143.21</b>	<b>7,981.90</b>	
Less: 1. Interest	1,093.64	1,264.57	787.10	2,941.74	2,362.92	2,843.78	
2. Other Un-allocable Expenditure							
3. Un-allocable Income							
<b>Total Profit Before Tax</b>	<b>865.71</b>	<b>864.90</b>	<b>1,269.07</b>	<b>2,769.14</b>	<b>3,780.29</b>	<b>5,138.11</b>	
<b>3. Capital Employed</b>							
a. Speciality Chemicals Business	81,486.10	81,111.67	79,486.78	81,486.10	79,486.78	77,019.49	
b. Pharma Business	21,440.14	21,333.46	7,068.48	21,440.14	7,068.48	7,554.32	
<b>Total</b>	<b>1,02,926.24</b>	<b>1,02,445.13</b>	<b>86,555.26</b>	<b>1,02,926.24</b>	<b>86,555.26</b>	<b>84,573.81</b>	

For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)  
 MANAGING DIRECTOR & CEO

Place : Hyderabad  
 Date : 13.02.2014

Part II					
Select Information for the Quarter Ended 31/12/2013					
	PARTICULARS	Quarter ended 31-12-2013	Quarter ended 30-09-2013	Quarter ended 21-12-2012	Quarter ended 31-03-2013
A	<b>PARTICULARS OF SHAREHOLDING</b>				
	<b>Public shareholding</b>				
	Number of Shares	10074058	10074058	7642776	9682136
	Percentage of Shareholding	62.17	62.17	54.85	60.28
	<b>Promoter and Promoter Group Shareholding</b>				
	<b>(a) Pledged/ Encumbered</b>				
	Number of Shares	2482455	3354455	15,77,455	22,52,455
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	40.5	54.72	25.07	35.31
	Percentage of shares (as a % of the total share capital of the company)	15.32	20.7	11.32	14.03
	<b>(b) Non -encumbered</b>				
	Number of Shares	3647270	2775270	47,13,711	41,26,335
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	59.5	45.28	74.93	64.69
	Percentage of shares (as a % of the total share capital of the company)	22.51	17.13	33.83	25.69

	Particulars			Quarter ended 31-12-2013
B	Pending at the beginning of the quarter			Nil
	Received during the quarter			2
	Disposed of during the quarter			2
	Remaining unresolved at the end of the quarter			Nil

For VIVIMED LABS LTD

Place : Hyderabad  
Date : 13.02.2014

(SANTOSH VARALWAR)  
MANAGING DIRECTOR & CEO



**P. MURALI & CO.,**  
CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470  
Fax : (91-40) 2339 2474  
E-mail : pmurali.co@gmail.com  
info@pmurali.com  
Website : www.pmurali.com

To  
The Board of Directors  
**M/S. VIVIMED LABS LIMITED**  
Plot No. 78-A, Kolhar Industrial Area  
Bidar- 585403,  
Karnataka


**Limited Review Report for the quarter ended 31<sup>st</sup> December, 2013**

We have reviewed the accompanying statement of unaudited financial results of M/S. **VIVIMED LABS LIMITED**, for the quarter ended 31<sup>st</sup> December, 2013 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co.  
Chartered Accountants



Place: Hyderabad  
Date: 12<sup>th</sup> February, 2014